Pharmaceutical Preparations · DE · CIK 1835597
PepGen develops oligonucleotide therapeutics to treat severe neuromuscular and neurologic diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 4, 2026: 3 sold $58K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Mcarthur James GPresident and CEO | Sell | 5,144 | $6.23 | $32K |
| Mar 4, 2026 | Donnelly NoelChief Financial Officer | Sell | 2,032 | $6.23 | $13K |
| Mar 4, 2026 | Streck PaulEVP, Head of R&D | Sell | 1,832 | $6.23 | $11K |
| Mar 4, 2026 | Mcarthur James GPresident and CEO | Sell | 131 | $6.33 | $829 |
| Mar 4, 2026 | Donnelly NoelChief Financial Officer | Sell | 52 | $6.33 | $329 |
| Mar 4, 2026 | Streck PaulEVP, Head of R&D | Sell | 47 | $6.29 | $296 |
| Sep 30, 2025 | Oxford Science Enterprises PlcOther | Buy | 200,000 | $3.20 | $640K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.